|
- CureVac - Revolutionizing mRNA for life.
CureVac is a global biopharmaceutical company with more than 20 years of experience in developing the mRNA technology for medical purposes
- News - CureVac
CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b 3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- Technology - CureVac
With mRNA in our sight, the CureVac method was developed from the cumulation of many years of work, research and nucleotide analysis — all in the name of overcoming the instability of mRNA molecules
- About Us - CureVac
With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical purposes – because we saw opportunities where others saw obstacles
- CureVac - Wir revolutionieren die mRNA für das Leben der Menschen.
CureVac ist ein globales biopharmazeutisches Unternehmen mit über 20 Jahren Erfahrung in der Entwicklung der mRNA-Technologie für medizinische Zwecke
- CureVac Announces Financial Results for the Third Quarter and First . . .
CureVac N V (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the third quarter and first nine months of 2025 and provided a business update
- BioNTech Announces Strategic Transaction to Acquire CureVac in Public . . .
Following the closing of the transaction, CureVac’s operating subsidiary will become a wholly owned subsidiary of BioNTech As part of this plan, BioNTech will integrate CureVac’s state-of-the-art research and manufacturing site in Tübingen
- Become part of the RNA people - CureVac
“I started at CureVac in 2006 and I am proud to be one of the RNA people We are not just developing new drugs, but a completely new technology that is able to revolutionize medicine And I have the opportunity to help make that happen ”
|
|
|